课题基金 / 基金详情

ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART

ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART
ACTG 328——在接受 HAART 治疗的 HIV 患者中通过静脉注射或皮下注射重组人 IL 2
批准号：
6306677
负责人：
GILDON N BEALL
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6306677
关键词：
AIDS therapy HIV infections clinical research drug administration routes helper T lymphocyte human subject human therapy evaluation immunotherapy interleukin 2 intravenous administration recombinant proteins

项目摘要

项目成果

GILDON N BEALL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Highly active antiretroviral treatment (HAART) of HIV infection is associated with dramatic fall in the amount of HIV in the blood. The effects on the immune system are positive but less dramatic. Restoration of the immune system is now a goal of chronic HIV therapy. Interleukin-2 is a substance which is naturally pro duced by the body's CD4 cells. People with HIV-1 infection do not produce enough IL-2. IL-2 has been shown to increase CD4 cells in HIV-1 patients by 2-4fold. Trials with intravenous IL-2 produced much toxicity in theform of "flu" symptoms
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART
ACTG388 EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ FIXED DOSE COMBINAT
PHYSIOLOGIC TESTOSTERONE REPLACEMENT IN HIV INFECTED WOMEN
PHASE I/II DOSING SAFETY AND ANTIVIRAL ACTIVITY OF HYDROSYUREA ALONE/COMBINED
海外基金